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Abstract
Background: The incidence of the para-aortic lymph node metastasis (PALM) in patients with advanced gastric
cancer is 6 to 33 %. The prognosis is poor and the 5-year survival rate is only 12 to 23 % after gastrectomy with
super-extended lymph node dissection. We applied an individualized comprehensive treatment for affected
patients including neoadjuvant chemotherapy via intra-arterial and intravenous administration, surgery and
radiotherapy, to investigate the safety and prognostic value.
Methods: Between January 2005 and December 2010, 47 advanced gastric cancer patients with PALM received 5-Fu
(370 mg/m2) and leucovorin (200 mg/m2) intravenously on days 1–5, and intra-arterial infusion of etoposide (80 mg/m2)
and oxaliplatin (80 mg/m2) on days 6 and 20, repeated 2 cycles. Patients achieved PR or CR of the para-aortic lymph node
(PAL) were performed D2 dissection, followed by 6 cycles chemotherapy with XELOX regimen, oxaliplatin (130 mg/m2)
on day 1 and xeloda (1000 mg/m2) on days 1 to 14 of a 28-day cycle, and radiotherapy to the region of PALM.
Results: Forty-six patients completed 2 cycles of neoadjuvant chemotherapy. The overall response rate of the primary
tumor was 80.4 % (37/46). The response rate of PAL was 76.1 % (35/46). Thirty-two patients underwent D2 dissection and
six cases achieved pathological complete response (pCR). The toxicity profile was well tolerable and there was no
treatment-related death. The median survival time for all patients was 23 months, and for nonsurgical and surgical
patients were 12 and 29 months (p < 0.001), respectively. The 1-year, 2-year and 3-year survival rate was 70.96, 43.27 and
35.48 % for all patients, and for surgical patients was 96.875, 68.75, and 40.63 %.
Conclusion: Advanced gastric cancer patients with PALM can obtain a survival benefit from neoadjuvant chemotherapy,
subsequent surgery and radiotherapy.
Trial registration: Current Controlled Trials ChiCTR-TRC-12002046.
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Background
Gastric cancer is one of the most common malignancies
worldwide, and its incidence in China alone accounts for
nearly half of all cases around the world [1, 2]. Most cases
of gastric cancer in China are diagnosed as advanced gastric
cancer [3]. Moreover, several studies indicated that more
than 20 % of the patients with advanced gastric cancer
show lymph node group No. 16 (para-aortic lymph node,
PAL) metastasis, which is considered as distant metastasis
by the UICC (Union Internationale Contre le Cancer)
TNM classification and usually indicates a poor prognosis
[4–7]. For these cases, gastrectomy with more radical
extended lymphadenectomy, D2 plus para-aortic node
dissection (PAND), has been practiced. However, several
randomized clinical trials concluded that there was no sur-
vival benefit of PAND over standard D2 lymphadenectomy
[8–10]. In order to improve locoregional control of gastric
cancer and survival, multimodal treatment involving
chemotherapy or radiotherapy in addition to surgery should
be considered as a promising treatment strategy.
Survival benefits from adjuvant chemotherapy or
radiotherapy have been demonstrated in previous studies
[11–13]. However, the response rate of preoperative
chemotherapy for advanced gastric cancer is less than
50 %. A pilot study in Japan applied a method of oral ad-
ministration of S1 and local radiotherapy to treat gastric
cancer with severe local infiltration and metastasis.
Twelve eligible patients were enrolled. R0 resections
were performed in 11 patients (91.7 %). A pathologic re-
sponse was observed in ten patients (83.3 %) [14]. Based
on the same theory, since 2005, we started a pilot study
performing an individualized comprehensive treatment
for gastric cancer patients with para-aortic lymph node
metastasis (PALM), which including combination of
intravenous and intra-arterial neoadjuvant chemother-




The protocol was approved by Chinese Ethics Committee
of Registering Clinical Trials, ChiECRCT and Independent
Institutional Review Board (IRB) of Jinling Hospital. The
trial is registered on clinicalTrialecrf.org and has the iden-
tification number ChiCTR-TRC-12002046.
Patient eligibility
From January 2005 to December 2010, 47 out of a total of
876 hospitalized gastric cancer patients diagnosed with
PALM enrolled in this study. All cases were diagnosed by
endoscopic biopsy. The primary tumor, local infiltration
and lymph node metastasis were valued by contrast en-
hanced CT scan and endoscopic ultrasound. Laparoscopy
combined with peritoneal cytology was performed in pa-
tients with potentially liver and peritoneal metastases.
Eligibility criteria included: 1. Histologically proven
gastric cancer; 2. Presence of para-aortic lymph node
metastasis, evaluated by CT scan; 3. 35–70 years of age; 4.
Performance status (PS) ≤1 on the Eastern Cooperative
Oncology Group (ECOG) scale [15]; 5. no prior anti-tumor
therapy; 6. Agreed to accept intravenous and intra-arterial
chemotherapy and signed informed consent; 7. Adequate
organ and bone marrow functions.
Exclusion criteria included: 1. Distant hematogenous
metastasis; 2. Peritoneal dissemination; 3. Acute perfor-
ation, massive hemorrhage and complete obstruction which
needed emergency services; 4. Serious or uncontrolled sys-
temic diseases; 5. Chemotherapy drug allergies; 6. Pregnant
or lactating; 7. With other malignancies.
The 6th edition UICC TNM classification is used for pre-
operative staging, and the number of lymph node stations
was determined according to the Japanese Gastric Cancer
Association (JGCA) classification [16].
Treatment protocol
All patients received 2 cycles of neoadjuvant chemotherapy
with a regimen of 5-Fu/leucovorin/etoposide/oxaliplatin
combinations via intravenous and intra-arterial administra-
tion. 5-Fu (370 mg/m2) and leucovorin (200 mg/m2) was
administered by intravenous infusion on day 1–5. Intra-
arterial administration of etoposide (80 mg/m2) and oxali-
platin (80 mg/m2) was performed by Seldinger method on
day 6 and 20, the catheter was inserted through femoral
artery into the celiac artery and the chemicals were injected
initially at relatively high doses, followed by 14 days’ rest.
After 2 cycles of neoadjuvant chemotherapy, the che-
motherapeutic response was evaluated using contrast-
enhanced CT scan by two experienced radiologists, who
were blinded to any of the clinical data independently,
according to the Response Evaluation Criteria in Solid
Tumors (RECIST) guidelines [17]. Patients were then di-
vided into group A with complete response (CR) or par-
tial response (PR) of PAL, or group B with stable disease
(SD) or progressive disease (PD). Patients of group A
underwent gastrectomy with D2 lymph node dissection,
followed by 6 cycles chemotherapy with the regimen of
XELOX, oxaliplatin (130 mg/m2) on day 1 and xeloda
(1000 mg/m2) on days 1 to 14 of a 28-day cycle, and
radiotherapy to the region of PALM. Patients of group B
continued chemotherapy and radiotherapy when neces-
sary without surgery. Treatment programs seen in Fig. 1.
For radiotherapy, blood routine test, hepatic and renal
function test and CT scan were performed before radio-
therapy. Gross tumor volume (GTV) was determined
based on CT tumor visualizations before the first treat-
ment. Planning target volumes (PTV) were GTV plus a
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2–3 mm margin. Total doses ranged from 45 to 51 Gy
(median 48 Gy).
Evaluation and statistic analysis
Tumor responses to preoperative chemotherapy were
evaluated using RECIST, based on CT scanning [17].
The histological response was evaluated according to the
histological criteria of the JCGC [18]. Briefly, histological
evaluation was based on the proportion of the tumor af-
fected by degeneration or necrosis: G3, no viable tumor
cells remain; G2, viable tumor cells remain in less than
1/3 of the tumor area; G1, viable tumor cells remain in
more than 1/3 but less than 2/3 of the tumor area; G0,
no evidence of treatment effect. All the adverse events
during chemotherapy and postoperative morbidity were
recorded. National Cancer Institute Common Toxicity
Criteria version 3.0 was applied to assess chemotherapy-
related toxicity.
All patients were followed up according to the insti-
tutional protocol. Tumor markers including serum
carcinoembryonic antigen (CEA), CA19-9 were exam-
ined every 3 months. Chest X-ray and abdominal/pelvic
CT scan were performed every 6 months. Gastroscopy
was also required each year. PET scan was suggested
when recurrence was suspected. The frequency of
follow-up is trimonthly in the first 2 years and every six
months after two years. Overall survival (OS) was de-
fined as the interval from the initial date of neoadjuvant
chemotherapy to the date of death from any cause. The
1 year, 2 year and 3 year survival rate was calculated
using the Kaplan-Meier method. Statistical analysis was
performed with SPSS version 19.0 (SPSS Inc., USA).
Results
Between January 2005 and December 2010, 47 patients,
out of a total of 876 hospitalized gastric cancer patients,
including 33 men and 14 women, enrolled into the
present study. The characteristics of these patients are
shown in Table 1. Among 47 patients, nine patients had
Borrmann type 2 tumors, 30 patients had Borrmann
type 3 tumors and eight patients had Borrmann type 4
Fig. 1 Treatment programs process
Table 1 The characteristics of gastric cancer patients with PALM


















JCGC Japanese classification of gastric carcinoma
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tumors. Endoscopic ultrasonography and CT scan
showed that tumor has invaded the serosa in all cases
and adjacent tissues in 13 cases. All patients had re-
gional lymph node metastasis, including four cases with
N1 lymph node status, 23 cases with N2 and to 20 cases
with N3.
Response and toxicity of neoadjuvant chemotherapy
Forty-six patients completed two cycles of neoadjuvant
chemotherapy, and five of them received enteral nutri-
tion though nose intestine. Responses of chemotherapy
and all adverse events are shown in Table 2. The clinical
overall response rate of primary tumor (CR + PR) was
80.4 % (37/46). Seven cases (15.22 %) were SD and two
patients (4.35 %) were PD. Meanwhile, the response rate
of PAL according to RECIST was 76.1 % (35/46), in
which eight cases were CR and 27 cases were PR.
There were no treatment-related deaths. The most
frequent toxicities were nausea, vomiting and diarrhea.
Among the hematological adverse events, 6.52 % of
patients experienced grade 3–4 anemia and leukopenia.
No abnormal results for liver or renal function tests
were observed in grade 3–4.
Surgery
Thirty-five cases were CR or PR of PAL. Thirty-two pa-
tients divided to group A and underwent D2 dissection:
total gastrectomy in 16 patients, distal gastrectomy in 14
patients and total gastrectomy with splenectomy in two
patients. There were three patients transferred to group
B owing to unresectable primary tumor with severe infil-
tration to the celiac artery and hepatoduodenal ligament.
All patients had recovered and been discharged.
Pathological response
In 32 postoperative resected specimens, G1, G2, and G3
response were observed in 11 cases, 15 cases and six
cases, respectively.
Local radiotherapy
Thirty-one patients in group A received radiotherapy. The
region of PAL was evaluated again by CT scan before radio-
therapy. One patient’s PAL with CR after neoadjuvant
chemotherapy appeared again, so 25 patients out of 31
remained PALM. After radiotherapy, six cases were CR, 15
cases were PR, four cases were SD and no PD. In group B,
one patient quitted after 4 cycles of chemotherapy. Five
patients underwent radiotherapy because of severe back
pain. There were no treatment related deaths.
Follow-up and survival
By March 2013, nine patients were still alive, and the lon-
gest survival time is 59 months. The survival curves for all
patients, patients in group A and group B are shown in
Figs. 2 and 3. The median survival time for all patients
was 23 months (95%CI, 18.686–27.314). And the median
survival time for group A and group B were 29 months
(95%CI, 23.624–34.376 p < 0.001) and 12 months (95%CI,
9.555–14.445 p < 0.001), respectively. The 1-year, 2-year
and 3-year survival rate was 70.96, 43.27 and 35.48 % for
all patients, and was 96.87, 68.75 and 40.63 % for patients
in group A.
Discussion
Para-aortic lymph nodes metastasis (PALM) is the last-tier
lymph nodes for intra-abdominal metastasis of gastric can-
cer. The incidence of metastasis in the para-aortic lymph
nodes (PLA) was 6 to 33 %. The 5-year survival for these
patients is only 12 to 23 %. There is no survival benefit of
aggressive surgical treatment, D2 plus para-aortic lymph
node dissection [8–10]. Recently, several clinical trials for
the treatment of advance gastric cancer have been carried
out in Japan [15, 16], but there’s none for patients with
PALM. To improve the survival of patients with PALM, it
is necessary to try new therapeutic strategies, including pre-
operative chemotherapy and irradiation. Therefore, our
study here may provide a practical treatment strategy for af-
fected patients.
Table 2 The response and effects of neoadjuvant
chemotherapy
Characteristic Number of patients Percent (%)
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CR complete response; PR partial response; SD stable disease; PD
progressive disease
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In most of the phase III clinical trails, the response rate
of preoperative chemotherapy for advanced gastric cancer
is less than 50 %. A pilot study in Japan applied the
method of oral administration of S1 and local radiother-
apy to treat gastric cancer with severe local infiltration
and metastasis, which showed a response rate of 83.3 %
for 12 patients and the 3-year survival rate was 58.3 %
[14]. Our neoadjuvant chemotherapy approach via intra-
arterial injection is based on the same theory, which
strengthens local effects on the primary tumor on the
basis of systemic administration. The response rate was
80.4, and 68.1 % cases achieved R0 resection. The overall
median survival time was 23 months. The toxicity profile
of this regimen was well tolerable and all patients with CR
or PR were able to safely undergo surgery.
Since the 1980s, gastrectomy with more radical extended
lymphadenectomy (D3, superextended lymphadenectomy)
has been practiced at many specialized centers in Japan.
However, patients would be too weak after neoadjuvant
chemotherapy to perform the aggressive surgery. A ran-
domized clinical trial JCOG0001 was conducted in Japan,
the patients received two or three cycles of chemotherapy
with irinotecan (70 mg/m2 on days 1 and 15) and cisplatin
(80 mg/m2 on day 1), and then underwent surgery. There
were three treatment-related deaths out of 55 enrolled
patients and the trail was terminated, which indicated that
intensive preoperative chemotherapy followed by D3
surgery is very difficult to conduct in practice [19]. There-
fore, in the present study, when patients achieved complete
response (CR) or partial response (PR) after 2 cycles of neo-
adjuvant chemotherapy, gastrectomy with D2 lymph node
dissection would be performed and followed by postopera-
tive radiotherapy to the region of PALM confirmed by CT
scan. Radiotherapy was conducted even if CR of PLA
achieved, because CR evaluated by CT scan doesn’t mean
pathological complete response, and radiotherapy was for
the management of potential micrometastasis. Resection of
the primary tumor would not improve the survival when
PALM exacerbated. In this case, chemotherapy should be
continued and radiotherapy should be considered.
There is no doubt that gastrectomy with regional
lymph node dissection contributes to improve patient
outcomes, actually, gastrectomy with D2 lymphadenec-
tomy is still the gold standard of treatment for advanced
gastric cancer. However, multimodal treatment involving
chemotherapy and radiotherapy in addition to surgery is
now thought to be a promising treatment strategy. Sur-
vival benefits from neoadjuvant chemotherapy or radio-
therapy have been demonstrated in many studies. Here,
to improve the survival of advanced gastric cancer pa-
tients with PALM, we used an individualized compre-
hensive treatment, including neoadjuvant chemotherapy
Fig. 2 Kaplan-Meier overall survival for all patients
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via intra-arterial and intravenous administration, surgery
and radiotherapy. The results of our study demonstrate
the individualized comprehensive treatment was safe
and effective and can benefit advanced gastric cancer pa-
tients with PALM.
Conclusion
Gastric cancer patients with PALM can obtain a survival
benefit from neoadjuvant chemotherapy, subsequent
surgery and radiotherapy.
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